LEUKEMIA TRANSLOCATIONS-PANEL 3

The panel analyzes genetic alterations associated with leukemia, offering insight into molecular abnormalities that can affect treatment and prognosis.

Also known asLeukemia Translocation Panel 3 Leukemia Translocation Panel 3

Available via

Home Collection, Lab Visit

Contains

11 parameters

Earliest reports in

7 Working Days

Test details

LEUKEMIA TRANSLOCATIONS-PANEL 3 Package in Vadodara Overview

What is Leukemia Translocation Panel 3 test?

Leukemia Translocation Panel 3 is a molecular cytogenetic test designed to detect specific chromosomal translocations and gene rearrangements commonly associated with acute and chronic leukemias. These genetic translocations result in fusion genes that play a critical role in the onset, classification, and progression of leukemia. Leukemia Translocation Panel 3 test typically uses RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) or FISH (Fluorescence In Situ Hybridization) to identify these fusion events, providing valuable diagnostic and prognostic information.

Parameters Covered : Gene Covered: (t(1;11) (P32;Q23), t(1;11) (P21;Q23), t (4;11) (Q21;Q23), t (6;11) (Q27;Q23), t(9;11) (P22;Q23), t(10;11) (P12;Q23), t(11;17) (Q23;Q21), t(11;19) (Q23;P13.1), t(11;19) (Q23;P13.3), DUP, MLL (11Q23), t(X;11) (Q13;Q23))

 

Why consider Leukemia Translocation Panel 3 test?

Leukemia Translocation Panel 3 test can be considered

  • To confirm the diagnosis of specific leukemia subtypes based on genetic abnormalities.
  • To identify prognostic markers that predict disease behavior and treatment response.
  • To help in treatment planning, including the use of targeted therapies (e.g., tyrosine kinase inhibitors).
  • To monitor minimal residual disease (MRD) or detect relapse in patients previously treated for leukemia.

Who should get tested for Leukemia Translocation Panel 3 test?

Leukemia Translocation Panel 3 test is generally recommended for:

  • Patients suspected or newly diagnosed with acute or chronic leukemia.
  • Individuals with abnormal blood counts or bone marrow findings suggesting a hematologic malignancy.
  • Patients whose clinicians require molecular confirmation of specific translocations for diagnosis or therapy selection.
  • Cases where standard cytogenetic tests are inconclusive.

More Information

OTHER NAMES: Leukemia Molecular panel, Leukemia Prognostic Panel, Leukemia translocations,

 

Leukemia is a cancer of the blood and bone marrow. In simple terms, cancer is defined as the uncontrolled growth of abnormal cells. Cancer can develop anywhere in the body. In leukemia, this rapid, out-of-control growth of abnormal cells takes place in the bone marrow. These abnormal cells then spill into the bloodstream. Unlike other cancers, Leukemia generally doesn’t form into a mass (tumour) that can be seen in imaging tests, such as X-rays.

 

Preparations

No special preparations needed

Test included
LEUKEMIA TRANSLOCATIONS-PANEL 3 includes 11 parameters

  • Specimen Source
  • Preliminary Report
  • T(4;11) (q21; Q23)
  • T(6;11) (q27; Q23)
  • T(9;11) (p22; Q23)
  • T(10;11) (p12; Q23)
  • T(11;19) (q23; P13.1)
  • T(11; 19) (q23; P13.3)
  • Rbm15-mkl1 [t(1;22)]
  • Dek-can [t( 6;9)]
  • Set-can [t(9;9)]

Test code

1627

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
Edta Whole BloodLavender Vacutainer3 ML
Heparin Whole BloodGreen Vacutainer3 ML

Specimen stability information

Edta Whole Blood, Heparin Whole Blood

Collection instructions

Clinical History

Specimen rejection criteria

Test run frequency

Every Day TIME - 09:30

Turn around time

7 Working Days

Performing locations

Department

  • Advanced Molecular Diagnostics R&d

CPT and Loinc codes

LEUKEMIA TRANSLOCATIONS-PANEL 3

9000